Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sibeprenlimab, an antibody targeting APRIL.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Mibavademab, an antibody targeting LEPR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lusvertikimab, an antibody targeting IL-7R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lemzoparlimab, an antibody targeting CD47.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Latozinemab, an antibody targeting Sortilin.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Imsidolimab, an antibody targeting IL-36R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Erfonrilimab, an antibody targeting PD-L1 × CTLA-4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Divozilimab, an antibody targeting CD20.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Dafsolimab, an antibody targeting CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bentracimab, an antibody targeting AR-C124910XX.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Amlitelimab, an antibody targeting OX40L.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Acasunlimab, an antibody targeting PD-L1 × 4-1BB.